Dendritic cells in the skin – potential use for melanoma treatment

Marsafy, Sanaa El; Bagot, Martine; Bensussan, Armand; Mauviel, Alain

doi:10.1111/j.1755-148x.2008.00532.x

Cited by 15 publications

(14 citation statements)

References 151 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These markers have been associated with dendritic cell maturation and have been shown to be required for antigen presentation (22, 23). CD11c + cells that emigrated from the vaccinated skin showed high expression levels of the cell surface markers MHC II and CD205 and a low expression level of CD8 (Fig.…”

Section: Resultsmentioning

confidence: 99%

Local Response to Microneedle-Based Influenza Immunization in the Skin

Martı́n

Weldon

Zarnitsyn

et al. 2012

mBio

View full text Add to dashboard Cite

ABSTRACTMicroneedle patches (MN) provide a novel method of vaccine delivery to the skin with the objective of targeting the large network of resident antigen-presenting cells to induce an efficient immune response. Our previous reports demonstrated that cutaneous delivery of inactivated influenza virus-coated MN to mice protects against lethal infection. Protection is correlated with sustained levels of anti-influenza virus serum antibodies, hemagglutination inhibition titers, and robust cellular responses that are often stronger than those generated by intramuscular vaccination. Here we dissect the early events occurring in murine skin after microneedle delivery of inactivated influenza virus. We demonstrate correlation of immunization against influenza virus with a local increase of cytokines important for recruitment of neutrophils, monocytes and dendritic cells at the site of immunization. We also observed prolonged antigen deposition, and migration of matured dendritic cells bearing influenza virus antigen from the skin.IMPORTANCEThe immunological mechanisms by which MN vaccination confers protective immunity are not well understood. The present study provides a first analysis of the early immune events after microneedle-based vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Local Response to Microneedle-Based Influenza Immunization in the Skin

Martı́n

Weldon

Zarnitsyn

et al. 2012

mBio

View full text Add to dashboard Cite

show abstract

“…Surgical treatment is effective for early stage melanoma, but new strategies are required for patients with advanced melanoma, which is highly resistant to conventional chemo‐ and radiation therapy. One such strategy is vaccination with dendritic cells (DCs) as an active immunotherapy (El Marsafy et al., 2009; Jandus et al., 2009; Nestle et al., 1998). DCs are unique specialized antigen‐presenting cells that are capable of stimulating naive T cells during primary immune responses and of inducing antigen‐specific cytotoxic T lymphocytes (CTLs) and helper T cells.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

Nakai

Hartmann

Kishimoto³

et al. 2010

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

show abstract

“…For in vitro-generated DC-based vaccine therapy for cancer patients, DCs are prepared by the culture of CD34 + HPCs in the presence of GM-CSF, TNF-α, and Flt3L or by culturing blood-derived monocytes in the presence of GM-CSF and IL-4 (El Marsafy et al 2009). Of note, DCs derived from CD34 + HPCs contain CD1a + CD14 - LC-type DCs.…”

Section: Resultsmentioning

confidence: 99%

Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity

Fujita

Suárez‐Fariñas

Mitsui

et al. 2012

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Purpose Langerhans cells [LCs] are dendritic cells [DCs] localized to the epidermis. They should be the first antigen presenting cells to encounter squamous cell carcinoma (SCC). The aim of this study was to investigate the ability of LCs isolated from human SCC to induce T cell proliferation and polarization. Experimental design We investigated the ability of LCs from SCC and peritumoral skin to induce T-cell proliferation and polarization. We also studied the effect of SCC supernatant on the ability of LCs from normal skin, in vitro generated LCs, and DCs to activate and polarize T cells. Results LCs from SCC were stronger inducers of allogeneic CD4+ and CD8+ T-cell proliferation and interferon (IFN)-γ production than LCs from peritumoral skin. We found that tumor supernatants were rich in immunosuppressive cytokines; despite this, allogeneic CD4+ and CD8+ T-cell proliferation and IFN-γ induction by LCs were augmented by tumor supernatant. Moreover, tumor supernatant facilitated IFN-γ induction by in vitro generated LCs, but suppressed the ability of in vitro generated DCs to expand allogeneic CD4+ and CD8+ T cells. Conclusions We have demonstrated that LCs from SCC can induce type-1 immunity. Tumor supernatant induces IFN-γ induction by in vitro generated LCs. This contrasts greatly with prior studies showing that DCs from SCC cannot stimulate T cells. These data indicate that LCs may be superior to DCs for SCC immunotherapy and may provide a novel rationale to harnessing LCs for the treatment of cancer patients.

show abstract

Dendritic cells in the skin – potential use for melanoma treatment

Abstract: SummaryMelanoma is an aggressive malignancy with poor prognosis. Eradication of tumor cells requires an effective interaction between melanoma cells and different players of the immune system. As the most potent

Cited by 15 publications

References 151 publications

Local Response to Microneedle-Based Influenza Immunization in the Skin

Local Response to Microneedle-Based Influenza Immunization in the Skin

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity

Contact Info

Product

Resources

About